相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics
Michelle F. Richter et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2019)
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile
Tarun Mathur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
Alexander G. Vandell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus
Tarani Kanta Barman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV
Syed Lal Badshah et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent progress in the discovery and development of DNA gyrase B inhibitors
Michaela Barancokova et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Predictive compound accumulation rules yield a broad - spectrum antibiotic
Michelle F. Richter et al.
NATURE (2017)
Solithromycin rejection chills antibiotic sector
Brian Owens
NATURE BIOTECHNOLOGY (2017)
Inhibitors of DNA Gyrase-GyrB Subunit and/or Topoisomerase IV-ParE Subunit May Treat Infectious Diseases Caused by Antibiotic-Resistant Bacteria
Ahmed F. Abdel-Magid
ACS Medicinal Chemistry Letters (2017)
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
William O'Riordan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection
Victoria J. Savage et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB
Michael F. Mesleh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV
Victoria J. Savage et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review
Mohammed Afzal Azam et al.
BIOORGANIC CHEMISTRY (2015)
ESKAPEing the labyrinth of antibacterial discovery
Ruben Tommasi et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV
Hardwin O'Dowd et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases
Gregory S. Basarab et al.
SCIENTIFIC REPORTS (2015)
A Novel Inhibitor of Gyrase B Is a Potent Drug Candidate for Treatment of Tuberculosis and Nontuberculosis Mycobacterial Infections
Christopher P. Locher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
Gregory S. Bisacchi et al.
ACS INFECTIOUS DISEASES (2015)
Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Tihomir Tomašić et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability
Anne-Laure Grillot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases
Neil R. Stokes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors
Lorraine C. Axford et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents
John Finn
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines
Maria Uria-Nickelsen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents
Gregory S. Basarab et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance
Katie J. Aldred et al.
NUCLEIC ACIDS RESEARCH (2013)
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase
Steven M. Ronkin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Benjamin D. Bax et al.
NATURE (2010)
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Alexandre Wohlkonig et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
Ivan Laponogov et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships
Paul S. Charifson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds
Trudy H. Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
分享论文
